The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Descriptive study of acute leukemia patients. Bone marrow aspirate or peripheral blood samples will be analyzed by next-generation sequencing for novel gene signatures and variations in transcriptional and epigenetic regulatory elements such as ARID5B and SALL4 variants.
Condition or disease
Diagnostic Test: Bone marrow aspirate or peripheral blood sample collection
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
1 Month to 30 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The study team will enroll approximately 50 subjects (age 1 month to 30 years) with newly diagnosed or relapsed acute leukemia.
Newly diagnosed or relapsed acute leukemia (AML or ALL)
Plan to undergo diagnostic bone marrow aspirate or peripheral blood if clinically indicated (i.e. WBC>50,000 and bone marrow contraindicated)
Age 1 month to 30 years
Understand and provide informed consent (subject if>18, legal guardian if<18)
Age 0 to 4 weeks
Treatment related leukemia or leukemia secondary to MDS
Situations that would limit compliance with study requirements or ability to willingly give consent